MedTrace Logo

Perennial Malaria Chemoprevention (PMC) in Cameroon

NCT05889052 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2080

Last updated 2025-01-09

No results posted yet for this study

Summary

The Plus Project will assess the impact, operational feasibility, efficacy, effectiveness, and cost-effectiveness of PMC. Specifically, the impact evaluation will involve monitoring a passive cohort of all children in the study area reporting all doses of SP received and the number of confirmed cases of malaria and anaemia, as well as a prospective active cohort of children who will have seven home visits over an 18-month period. The total number of participants is expected to be approximately 2,080 children in the areas served by 35 health centres in Cameroon. The results of this study will allow direct evaluation of the protective efficacy of PMC on malaria incidence, severe anaemia, and malaria mortality.

Conditions

Interventions

DRUG

Sulfadoxine pyrimethamine

Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)

Sponsors & Collaborators

  • Fobang Institutes Centre for Health Implementation and Translational Research

    collaborator UNKNOWN

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Wilfred Mbacham, ScD · Fobang Institutes Centre for Health Innovation and Translational Research

  • R Matthew Chico, MPH, PhD · London School of Hygiene and Tropical Medicine

Eligibility

Max Age
9 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-19
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Cameroon

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889052 on ClinicalTrials.gov